Compare Manulife Financial Corporation (MFC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs TG Therapeutics Inc — how do they compare? Manulife Financial Corporation trades at $42.35 (market cap $69.48B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: Manulife Financial Corporation is far larger — about 8.5× TG Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and TG Therapeutics Inc for 16 Days on average.
| MFC | TGTX | |
|---|---|---|
Market Cap | $69.48B | $8.16B |
Volume | 1,347,508 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $44.77 | $59.06 |
52-Week Low | $31.64 | $26.94 |
Typical Hold Time | 119 Days | 16 Days |
Enterprise Value | $64.75B | $8.37B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.33, up 1.58% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $53.01B in 2025 to projected $57.5B in 2026, with net income margins around 11%. Recent institutional investments from Bank of America and executive appointments signal confidence. However, the stock trades above the $34.24 consensus price target, suggesting limited near-term upside.
The outlook remains mixed with solid fundamentals but valuation concerns. Investment opportunity lies in continued Asia growth and insurance sales momentum, while risks include premium valuation and potential earnings volatility. Analyst consensus leans bullish with 57% buy ratings, but technical indicators warn of near-term pressure.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
